An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. (Q39493859)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Gianluca Sala

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Rossano Lattanzio

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Nicola Tinari

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

S Traini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M D'Egidio

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

G Vianale

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

C Rossi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

E Piccolo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

P G Natali

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

R Muraro

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

S Iacobelli

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Consorzio Interuniversitario Nazionale per la Bio-Oncologia

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

English

0 references

publication date

8 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

1275-1286

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21822299%20AND%20SRC:MED&resulttype=core&format=json

Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Lapatinib in breast cancer: clinical experiences and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

ErbB receptors and signaling pathways in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Breast cancer: the upgraded role of HER-3 and HER-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

HER3 is a determinant for poor prognosis in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Phospholipase Cgamma1 is required for metastasis development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

ErbB-3 predicts survival in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322

Targeting ERBB receptors in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.322